Author:
Fukumoto Takeshi,Fujiwara Susumu,Sakaguchi Masanobu,Oka Masahiro,Nishigori Chikako
Reference10 articles.
1. Yamazaki N, Uhara H, Wada H, et al. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma. J Dermatol 2016; 43: 1146–53.
2. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117–26.
3. Yanagi T, Hata H, Homma E, Kitamura S, Imafuku K, Shimizu H. Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis. Clin Exp Dermatol 2017; 42: 781–5.
4. Fujisawa Y, Otsuka F, Japanese Melanoma Study Group F. Does adjuvant therapy improve the prognosis of stage II and stage III melanoma patients? An analysis of 831 cases. Jpn J Dermatol 2012; 122: 2305–11.
5. Matsumoto T, Yokota K, Sawada M, et al. Postoperative DAVIFN-therapy does not improve survival rates of stage II and stage III melanoma patients significantly. J Eur Acad Dermatol Venereol 2013; 27: 1514–20.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献